Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections
- PMID: 36977164
- PMCID: PMC10057134
- DOI: 10.3390/tropicalmed8030163
Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections
Erratum in
-
Correction: Srisuphanunt et al. Molecular Mechanisms of Antibiotic Resistance and Novel Treatment Strategies for Helicobacter pylori Infections. Trop. Med. Infect. Dis. 2023, 8, 163.Trop Med Infect Dis. 2023 Aug 29;8(9):429. doi: 10.3390/tropicalmed8090429. Trop Med Infect Dis. 2023. PMID: 37755917 Free PMC article.
Abstract
Helicobacter pylori infects approximately 50% of the world's population and is considered the major etiological agent of severe gastric diseases, such as peptic ulcers and gastric carcinoma. Increasing resistance to standard antibiotics has now led to an ever-decreasing efficacy of eradication therapies and the development of novel and improved regimens for treatment is urgently required. Substantial progress has been made over the past few years in the identification of molecular mechanisms which are conducive to resistant phenotypes as well as for efficient strategies to counteract strain resistance and to avoid the use of ineffective antibiotics. These involve molecular testing methods, improved salvage therapies, and the discovery of novel and potent antimicrobial compounds. High rates of prevalence and gastric cancer are currently observed in Asian countries, including Japan, China, Korea, and Taiwan, where concomitantly intensive research efforts were initiated to explore advanced eradication regimens aimed at reducing the risk of gastric cancer. In this review, we present an overview of the known molecular mechanisms of antibiotic resistance and discuss recent intervention strategies for H. pylori diseases, with a view of the research progress in Asian countries.
Keywords: Helicobacter pylori; antibiotic resistance; drug development; salvage therapy.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Front Cell Infect Microbiol. 2017 May 5;7:168. doi: 10.3389/fcimb.2017.00168. eCollection 2017. Front Cell Infect Microbiol. 2017. PMID: 28529929 Free PMC article. Review.
-
Review article: the global emergence of Helicobacter pylori antibiotic resistance.Aliment Pharmacol Ther. 2016 Feb;43(4):514-33. doi: 10.1111/apt.13497. Epub 2015 Dec 23. Aliment Pharmacol Ther. 2016. PMID: 26694080 Free PMC article. Review.
-
Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi: 10.12998/wjcc.v10.i19.6349. World J Clin Cases. 2022. PMID: 35979311 Free PMC article. Review.
-
Treatment of Helicobacter pylori infection: Where are we now?J Gastroenterol Hepatol. 2016 Dec;31(12):1918-1926. doi: 10.1111/jgh.13418. J Gastroenterol Hepatol. 2016. PMID: 27088632 Review.
-
Drug-Resistant Helicobacter pylori: Diagnosis and Evidence-Based Approach.Diagnostics (Basel). 2023 Sep 14;13(18):2944. doi: 10.3390/diagnostics13182944. Diagnostics (Basel). 2023. PMID: 37761310 Free PMC article. Review.
Cited by
-
Beyond antibiotics: probiotics as a promising ally against Helicobacter pylori.Front Pharmacol. 2025 Jul 11;16:1620870. doi: 10.3389/fphar.2025.1620870. eCollection 2025. Front Pharmacol. 2025. PMID: 40717984 Free PMC article. Review.
-
Challenges and Prospects for Eradication of Helicobacter pylori: Targeting Virulence Factors, Metabolism, and Vaccine Innovation.Pathogens. 2025 Jun 21;14(7):619. doi: 10.3390/pathogens14070619. Pathogens. 2025. PMID: 40732667 Free PMC article. Review.
-
Enhanced urease inhibitory activity of quercetin via conjugation with silver nanoparticles: synthesis, characterization, and DFT study.Sci Rep. 2025 Apr 7;15(1):11892. doi: 10.1038/s41598-025-96684-2. Sci Rep. 2025. PMID: 40195446 Free PMC article.
-
Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control.Diseases. 2024 Dec 3;12(12):311. doi: 10.3390/diseases12120311. Diseases. 2024. PMID: 39727641 Free PMC article. Review.
-
Antimicrobial combinations against Helicobacter pylori including benzoxadiazol-based flavodoxin inhibitors: in vitro characterization.Microbiol Spectr. 2024 Jan 11;12(1):e0262323. doi: 10.1128/spectrum.02623-23. Epub 2023 Dec 12. Microbiol Spectr. 2024. PMID: 38084974 Free PMC article.
References
-
- Hooi J.K.Y., Lai W.Y., Ng W.K., Suen M.M.Y., Underwood F.E., Tanyingoh D., Malfertheiner P., Graham D.Y., Wong V.W.S., Wu J.C.Y., et al. Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology. 2017;153:420–429. doi: 10.1053/j.gastro.2017.04.022. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous